Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "Sputnik"

50 News Found

We are marketing all our products globally: Samit Jain, MD, PLUSS
interviews | October 25, 2021

We are marketing all our products globally: Samit Jain, MD, PLUSS

Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business

Promising prospects for Indian pharma: CLSA
News | September 17, 2021

Promising prospects for Indian pharma: CLSA

CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report

Reliance Life Science gets go-ahead for Phase I clinical trial for Covid-19 vaccine
Drug Approval | September 04, 2021

Reliance Life Science gets go-ahead for Phase I clinical trial for Covid-19 vaccine

The trial will be conducted across eight sites in Maharashtra

SEC recommends Phase I clinical trials for Reliance’s Covid-19 vaccine candidate
News | August 27, 2021

SEC recommends Phase I clinical trials for Reliance’s Covid-19 vaccine candidate

The company has to approach the DCGI for approval to commence the trials

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
News | August 03, 2021

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr

The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
News | July 28, 2021

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr

The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.

Shilpa Medicare receives DRDO approval for 2DG manufacturing
News | June 26, 2021

Shilpa Medicare receives DRDO approval for 2DG manufacturing

2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country

Outlook intact for Dr. Reddy's Laboratories : ICICI Securities
News | May 18, 2021

Outlook intact for Dr. Reddy's Laboratories : ICICI Securities

India sales grew 23.5% YoY with consolidation of Wockhardt products

Dr. Reddy's Laboratories see marginal dip in FY 2021 PAT
News | May 15, 2021

Dr. Reddy's Laboratories see marginal dip in FY 2021 PAT

Dr. Reddy's Laboratories has reported total income of Rs.19338.9 crores during FY ended March 31, 2021

Dr. Reddy’s seeks approval to continue Phase 3 trial
News | January 13, 2021

Dr. Reddy’s seeks approval to continue Phase 3 trial

The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.

Latest Stories

IIHMR Start-ups inks MoU with BMCHRC & HCG Hospital

LVPEI raises awareness and funds for retinoblastoma treatment with WHITATHON Run

Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
Vinod Paremal President & MD, Evonik, India Region

Packaging